Amid Reforms, Brexit, UK IVD Firms Battle Funding And Adoption Issues
Executive Summary
The EU In Vitro Diagnostics Regulation and Brexit loom large for UK IVD companies, but manufacturers serving the $1.6bn UK IVD market have many other competing concerns. It’s the most challenging period in more than 15 years, according to the British In Vitro Diagnostics Association Chief Executive Doris-Ann Williams.
You may also be interested in...
UK Device, IVD Sector Cheered By New Funding Pledge For Accelerated Access Program
UK Government health minister James O'Shaughnessy has delighted local medtech innovators with the promise of a package of funding under the Accelerated Access Review (AAR).
Is The UK Still Open For Medtech Innovation And Reimbursement?
Confusing and ineffective channels of innovation adoption and a lack of funding hamper the UK's reputation as one of the world's health care capitals and a driver of care excellence – in spite of its global brands, NICE, MHRA and the NHS itself. But changes that should transform market access are in place and are worthy of close attention in the next two to three years.
UK Diagnostic Fret Over Loss of Support In Evidence Centers Restructure
Changes are afoot for the four UK Diagnostic Evidence Co-operatives that help generate clinical and cost-effectiveness data for innovative IVDs. Companies worry it could mean diagnostic industry needs get lost among broad medtech targets. Also, a roundup of the British In Vitro Diagnostics Association's key priorities, including the EU IVD Regulation, procurement issues, antimicrobial resistance, and of course, Brexit, highlighted at the group's 2016 annual meeting.